Pharmacogenomics (PGx) Gene Testing Helps Identify An Individual’s Best Possible Pharmaceutical Treatment

FDA online resources provide a comprehensive list of  pharmacogenomics biomarkers for FDA-approved drugs and medications for cancers, cardiovascular, lipid metabolism, diabetes, gastrointestinal, infectious diseases, neurological, pain, psychiatry and addiction, rheumatology, gynecology, and urological conditions. At the molecular level, certain genes are responsible for how the body processes different medications, and pharmacogenomics combines our understanding of medication metabolism with genetics. Genetic variations may determine the effectiveness or potential side effects to a specific medication. Let us help your physician and you to know your genetics to personalize your medication. The sample reports for comprehensive pharmacogenomics and for pain medication pharmacogenomics genetic testing illustrate the benefits of pharmacogenomics (PGx) genetic testing:

  • Identification of effective therapies by recognizing responders and non-responders
  • Optimization of drug dose
  • Reducing potential side effects and avoiding adverse events
  • Revealing potential harmful drug-drug interactions

 

 

Drug Class

 
ADHD Benzodiazepines Muscle Relaxants
Antiarrhythmics Chemotherapeutics NSAIDs
Anticoagulants Corticosteriods Opioids
Antidepressants CFTR Platelet Aggregation Inhibitors
Antidiabetics General Anesthetics Proton Pump Inhibitors
Antiepileptics Hepatitis Antivirals Statins
Antihypersensitives HIV/AIDS Thrombophilia
Antipsychotics Immunosuppressants

 

 

42 Genes Sampled

ABCB1, ABCG2, ADRA2A, ADRB1, AGT, CACNA1C, CES1, CFTR

COMT, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5

DPYD, DRD1, DRD2, DRD3, EDN1, F2, F5, GNB3, GRIK1, GSTA1

HTR1A, HTR2A, HTR2C, IFNL3, KCNIP1, LDLR, MTHFR,

NAT1, NR1H3, OPRM1, RYR1, SLC6A2, SLCO1B1, TPMT,

UGT2B10, UGT2B7 , VKORC1

 

 

Otogenetics PGx Panels

Medical Management – 42 genes

ABCB1, ABCG2, ADRA2A, ADRB1, AGT, CACNA1C, CES1, CFTR, COMT, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, DPYD, DRD1, DRD2, DRD3, EDN1, F2, F5, GNB3, GRIK1, GSTA1, HTR1A, HTR2A, HTR2C, IFNL3, KCNIP1, LDLR, MTHFR, NAT1, NR1H3, OPRM1, RYR1, SLC6A2, SLCO1B1, TPMT, UGT2B10, UGT2B7, VKORC1

Cardiovascular 

ABCG2, CACNA1C, CYP2C19, CYP2C9, CYP2D6, CYP3A4, Factor II, Factor V, MTHFR, SLCO1B1, VKORC1

Mental Health 

ADRA2A, COMT, CYP1A2, CYP2C19, CYP2D6, DRD2, GRIK4, HTR2A, MTHFR, OPRM1

Pain Management 

COMT, CYP1A2, CYP2C19, CYP2C9, CYP2D6, OPRM1

Oncology 

ABCB1, CYP2D6, CYP3A4, CYP3A5, COMT, DPYD, MTHFR, OPRM1, SLCO1B1, TPMT

Thrombosis Risk

F2, F5

 

 

Why Choose Gx™ PGx Testing For Your Pharmacogenomics?

Once the PGx test is completed, we want you to have the information you need to create a personalized approach to prescription medicine.

Comprehensive: include up to date genomic biomarkers in clinical pharmacogenomics

Accuracy: apply the most advanced sequencing technology to eliminate ambiguities at every genomic biomarker locus

Expertise: Experience in genetic testing for over 10 years

 

 

Reporting That Fits Your Needs

  • Reports are tailored to the recipient based on their clinical context
  • Highlighting of information critical to patient care
  • Visual decision-making aids to help decision making when trade-offs are required